Compare Stocks: AXLA, FLGC, LABT, and INM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	N/A
FLGC Flora Growth	$4.71 +4.7%	$3.16	$5.86 ▼ $47.00	$4.93M	1.9	39,454 shs	440,978 shs
INM InMed Pharmaceuticals	$1.36 -2.2%	$1.46	$0.58 ▼ $2.50	$4.61M	0.98	75,080 shs	10,307 shs
LABT Lakewood-Amedex Biotherapeutics	$1.99 +7.0%	$2.25	$1.66 ▼ $98.20	$4.41M	N/A	1.27 million shs	280,836 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
FLGC Flora Growth	+8.43%	-8.16%	+144.55%	+11.39%	-84.90%
INM InMed Pharmaceuticals	-2.16%	+5.43%	-14.47%	-8.72%	-42.37%
LABT Lakewood-Amedex Biotherapeutics	+6.99%	-10.36%	-11.16%	+415.41%	+198,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	N/A
FLGC Flora Growth	$4.71 +4.7%	$3.16	$5.86 ▼ $47.00	$4.93M	1.9	39,454 shs	440,978 shs
INM InMed Pharmaceuticals	$1.36 -2.2%	$1.46	$0.58 ▼ $2.50	$4.61M	0.98	75,080 shs	10,307 shs
LABT Lakewood-Amedex Biotherapeutics	$1.99 +7.0%	$2.25	$1.66 ▼ $98.20	$4.41M	N/A	1.27 million shs	280,836 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
FLGC Flora Growth	+8.43%	-8.16%	+144.55%	+11.39%	-84.90%
INM InMed Pharmaceuticals	-2.16%	+5.43%	-14.47%	-8.72%	-42.37%
LABT Lakewood-Amedex Biotherapeutics	+6.99%	-10.36%	-11.16%	+415.41%	+198,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXLA Axcella Health	0.00	N/A	N/A	N/A
FLGC Flora Growth	1.00	Sell	N/A	N/A
INM InMed Pharmaceuticals	1.00	Sell	N/A	N/A
LABT Lakewood-Amedex Biotherapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest AXLA, FLGC, LABT, and INM Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/9/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	LABT Lakewood-Amedex Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
6/24/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
FLGC Flora Growth	$57.61M	0.09	N/A	N/A	$12.21 per share	0.39
INM InMed Pharmaceuticals	$4.94M	0.91	N/A	N/A	$0.32 per share	4.25
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXLA Axcella Health	-$81.19M	-$19.25	N/A	N/A	N/A	N/A	N/A	-259.91%	N/A
FLGC Flora Growth	-$15.91M	-$32.49	N/A	N/A	N/A	-32.03%	-64.02%	-34.46%	N/A
INM InMed Pharmaceuticals	-$12.56M	-$1.64	N/A	N/A	N/A	N/A	-156.08%	-123.90%	9/23/2026 (Estimated)
LABT Lakewood-Amedex Biotherapeutics	-$3.85M	-$4.75	N/A	1.51	N/A	N/A	N/A	N/A	N/A

Latest AXLA, FLGC, LABT, and INM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/23/2026	Q4 2026	INM InMed Pharmaceuticals	-$94.4436	N/A	N/A	N/A	$2.06 billion	N/A
9/9/2026	Q4 2026	INM InMed Pharmaceuticals	N/A	-$1.43	N/A	-$1.43	N/A	N/A
8/14/2026	Q2 2026	LABT Lakewood-Amedex Biotherapeutics	N/A	-$2.75	N/A	-$2.75	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXLA Axcella Health	N/A	0.80	0.80
FLGC Flora Growth	N/A	2.08	1.79
INM InMed Pharmaceuticals	N/A	1.37	1.37
LABT Lakewood-Amedex Biotherapeutics	N/A	7.70	7.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXLA Axcella Health	65.07%
FLGC Flora Growth	36.01%
INM InMed Pharmaceuticals	20.12%
LABT Lakewood-Amedex Biotherapeutics	N/A

Insider Ownership

Company	Insider Ownership
AXLA Axcella Health	2.20%
FLGC Flora Growth	2.34%
INM InMed Pharmaceuticals	0.85%
LABT Lakewood-Amedex Biotherapeutics	5.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	No Data
FLGC Flora Growth	280	1.05 million	1.02 million	Not Optionable
INM InMed Pharmaceuticals	6	3.31 million	3.29 million	Not Optionable
LABT Lakewood-Amedex Biotherapeutics	5	2.37 million	2.24 million	N/A

AXLA, FLGC, LABT, and INM Headlines

Recent News About These Companies

Lakewood-Amedex gets IRB approval for diabetic foot ulcer trial

September 19 at 9:17 AM | streetinsider.com

Lakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

September 19 at 9:17 AM | tennessean.comT

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

September 18 at 8:13 AM | prnewswire.com

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

July 22, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

July 15, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

July 7, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.

June 25, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

June 22, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

June 16, 2026 | prnewswire.com

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers

May 27, 2026 | prnewswire.com

Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update

May 18, 2026 | benzinga.com

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

May 18, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

May 12, 2026 | prnewswire.com

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

April 28, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXLA, FLGC, LABT, and INM Company Descriptions

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Flora Growth NASDAQ:FLGC

$4.71 +0.21 (+4.67%)

As of 09/18/2026

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

InMed Pharmaceuticals NASDAQ:INM

$1.36 -0.03 (-2.16%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 09/18/2026 07:42 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

$1.99 +0.13 (+6.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.91 -0.08 (-4.02%)

As of 09/18/2026 07:56 PM Eastern

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection. As of March 2026, we hold 68 issued and 36 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets. We have successfully completed our first exploratory human clinical trials for our lead product, the broad-spectrum Bisphosphocin® (anti-bacterial) Nu-3, which is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). We plan to conduct an initial Phase 2a safety and dose response study, followed by a placebo-controlled Phase 2b dose comparative study to identify the optimal dose for Phase 3 trials and eventual commercialization. This study will also determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers. Additionally, we are advancing early-stage pipeline compounds and are focused on further characterizing them to identify the best clinical indications for non-clinical and clinical evaluation. Advancement of any of our product candidates to the commercialization stage is completely dependent on the outcome of clinical studies that are reviewed and approved by the FDA or other comparable regulatory authorities. Headquartered in University Park, Florida, we were originally incorporated in Delaware on July 11, 2006, under the name Nu Pharmas, Inc. (“Nu Pharmas”). We initially focused on antisense RNA research and the contract manufacturing of oligonucleotides. On April 9, 2007, Nu Pharmas acquired substantially all the assets of Renaissance Nutraceuticals, Inc., a Delaware corporation, and subsequently changed its name to Amedex Therapeutics, Inc. (“Amedex Therapeutics”). On November 11, 2007, Amedex Therapeutics acquired substantially all the assets of Lakewood Pharmaceuticals, Inc., a Delaware corporation. On February 1, 2008, Amedex Therapeutics changed its name to Lakewood-Amedex Inc. On June 5, 2025, the Company changed its name to Lakewood-Amedex Biotherapeutics Inc. and redomiciled as a Nevada corporation. Our corporate address is in University Park, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXLA, FLGC, LABT, and INM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXLA, FLGC, LABT, and INM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXLA, FLGC, LABT, and INM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXLA, FLGC, LABT, and INM Company Descriptions

Axcella Health NASDAQ:AXLA

Flora Growth NASDAQ:FLGC

InMed Pharmaceuticals NASDAQ:INM

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXLA, FLGC, LABT, and INM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXLA, FLGC, LABT, and INM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXLA, FLGC, LABT, and INM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXLA, FLGC, LABT, and INM Company Descriptions

Axcella Health NASDAQ:AXLA

Flora Growth NASDAQ:FLGC

InMed Pharmaceuticals NASDAQ:INM

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools